AI to aid trial recruitment, digital biomarker discovery across Clinerion network

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Yuichiro Chino)
(Image: Getty/Yuichiro Chino)

Related tags: AI, Artificial intelligence, Clinerion, RWE, Real world evidence, Patient recruitment

Clinerion is deploying Volv’s AI algorithms across its hospital network as part of a recently announced strategic collaboration that includes plans to bring an ‘enhanced value proposition’ to both companies’ expanded client base, says CEO.

Clinerion’s Patient Network Explorer (PNEx) uses data from electronic health records (EHRs) for clinical trial patient recruitment and real-world evidence (RWE) generation.

The company – which this year has inked a series of new partnerships​ across the globe – recently announced a strategic collaboration with Switzerland-based Volv.

Volv CEO Christopher Rudolf told us the basis of the relationship is to enhance Clinerion’s products as well as Volv’s methodologies, including its inTrigue artificial intelligence (AI) algorithms which enable clinical trial cohort selection and patient modeling for earlier diagnosis.

Read more: Artificial intelligence: Where are we now? And what comes next?

“Clinerion brings its rapidly expanding footprint of participating hospitals to the partnership and Volv brings it’s data science capabilities for patient finding and digital biomarker discovery,”​ said Rudolf.

Using Volv’s ‘patient cohort defining algorithms,’ Rudolf added that Clinerion will be able to identify patients at risk of diseases ‘much earlier.’

“Volv’s algorithms can be used to find more appropriate cohorts for clinical trials supporting Clinerion’s core business, but they will also to expand that business by providing a platform to roll-out tools that will now also look for and flag patients with a high risk of disease that have not already been diagnosed,”​ he explained.

For patients, the benefit is an earlier potential diagnosis, as well as a reduction of misdiagnosis and inappropriate treatment. Hospitals will see ‘reduced overall burden of care’ with patients moving into the correct clinical pathway sooner, Rudolf said.

“The benefit to our clients is that they have tooling that they can deploy to give earlier access of medication and treatments to patients in need,”​ he added. “For Volv and Clinerion’s customers, that provides a wider reach as well as a longer product lifecycle that is of value to their customers as they move from clinical trials and into product launch.”

The companies also will provide customers with real world evidence (RWE) to support customers’ market launch and commercialization strategies.

“This is a clear fit between two companies that have joint growth strategies​,” said Rudolf. “By partnering in this way, Volv and Clinerion have substantially increased their target markets and they will leverage their teams to grow their businesses with joint planned activities bringing this enhanced value proposition to their new larger target client base.”

Related news

Show more

Related products

show more

Overcoming Challenges of Clinical Data Review

Overcoming Challenges of Clinical Data Review

PerkinElmer | 10-Jun-2021 | Technical / White Paper

Clinical data review is intrinsic to clinical development, assuring patient safety, determining drug efficacy, and assessing data quality. It involves...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us


View more